Research
Hormonal
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists improve metabolic health in obesity and type 2 diabetes by lowering BMI, improving insulin sensitivity, and potentially activating thermogenic fat.
GLP-1 and GLP-1/GIP agonists are powerful tools for treating obesity and type 2 diabetes. They work by reducing appetite and improving how your body handles insulin and fat. These drugs have been shown to lead to significant weight loss (over 20% in some cases) and improve heart health. They are often used alongside lifestyle changes like diet and exercise.
StrongSupportsVERY_HIGH confidence
GLP-1 receptor agonists have been associated with favorable metabolic changes in obese human subjects such as lowering of BMI, improved ability of insulin to suppress lipolysis and hepatic glucose production, and reduction in hepatic steatosis... Prolonged treatment with GLP-1 receptor agonists have also been reported to activate thermogenic fat in humans.
Why this rating
Cites multiple randomized controlled trials and FDA approvals.
Source
Adipose Tissue and Metabolic Health
Sung‐Min An et al. · Diabetes & Metabolism Journal · 2023
narrative_reviewCited 136×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →